MedTrace Logo

Inflammatory Markers and Level of Cortical Hyperactivity

NCT05991830 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2025-11-20

No results posted yet for this study

Summary

Alzheimer's disease (AD) is a progressive and fatal neurodegenerative disease that is manifested by severe cognitive impairment mainly from late life (\>65 years). Clinical studies have shown that both systemic inflammation and cortical and hippocampal hyperactivity are features present in patients during the early stages of the disease. In this project we will seek to relate the levels of the proinflammatory cytokines interleukin-1beta, interleukin-6 and tumor necrosis factor-alpha with the level of cortical hyperactivity evaluated with the electroencephalographic changes induced by the GABAergic anesthetic propofol in older adults undergoing elective surgery.

Conditions

  • Cognition Disorder

Interventions

PROCEDURE

General anesthesia

Older adults during elective surgery under general anesthesia with propofol, frontal EEG will recorded and a baseline plasma sample will be taken

Sponsors & Collaborators

  • University of Chile

    lead OTHER

Principal Investigators

  • Pedro Lobos, PhD · University of Chile

  • Antonello Penna, MD, PhD · University of Chile

Eligibility

Min Age
60 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-01
Primary Completion
2025-07-31
Completion
2025-09-30

Countries

  • Chile

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05991830 on ClinicalTrials.gov